Korean Healthtech Must Rebuild Its Adoption Case Before Entering Global Markets

A Korean healthtech company may arrive in London with MFDS approval, hospital references, published results, and an impressive English sales deck. But while the product has crossed the border, its adoption case apparently has not. A new healthcare system will still evaluate the same technology against different patient populations, clinical pathways, assurance standards, purchasing structures, and policy priorities. International expansion only begins when domestic proof is treated as a foundation rather than a complete overseas proposition.

Korean Healthtech Exports Are Growing, but Adoption Remains Local

South Korea exported KRW 7.64 trillion, approximately USD 5.37 billion, in medical devices during 2025, according to the Ministry of Food and Drug Safety. Exports increased 2.2% year over year, reached 203 countries, and helped the sector record its sixth consecutive annual trade surplus.

Those results show that Korean medical technology is already crossing borders. Export value, however, does not reveal how deeply a product becomes embedded in another healthcare system or how much adaptation was required before institutional use became credible.

Dr Phil Jewell, Programme Manager for SETT Medtech Innovation Pathways at University Hospital Southampton NHS Foundation Trust, has worked across hospital innovation, university collaboration, research funding, and healthcare technology support. As the exclusive interview on medtech adoption barrier continued with KoreaTechDesk, he identified a common mistake among companies entering a new health market.

“One of the most common mistakes international healthtech startups make is assuming that success in one healthcare system will automatically translate to another.”

Approval, evidence, reference customers, and domestic adoption can establish credibility at home. However, a foreign healthcare system still has to decide whether the product can truly belong within its own structure.

Domestic Medical Evidence Does Not Travel Unchanged

Previous clinical results remain valuable overseas, but their meaning depends on the conditions under which they were produced. A medical AI model validated in Korea may encounter different patient characteristics, clinical practices, equipment, coding conventions, and data quality abroad.

A 2026 Nature Health scoping review examined 75 studies involving silent trials, which test medical AI prospectively in intended clinical environments without influencing patient care. The review found reduced accuracy in some studies when development and evaluation settings differed because of data acquisition, patient populations, clinical practices, incomplete data, and inconsistent electronic health record coding.

The review also identified a common performance decline when models moved beyond retrospective testing into silent or prospective evaluation. This reflects the limits of single-setting validation and highlights the need for local evaluation when models are deployed in new clinical environments.

Local clinical evidence should therefore be treated as part of medical device market entry. It can reveal which findings remain transferable, where the intended use needs adjustment, and what overseas clinicians still need to verify.

The UK Changes the Adoption Case

The United Kingdom illustrates how quickly the market-access stack changes after a product leaves Korea. Great Britain and Northern Ireland operate under different regulatory arrangements, which already makes “entering the UK” too broad for an execution plan.

In Great Britain, medical devices must be registered with the Medicines and Healthcare products Regulatory Agency before market placement. A manufacturer based outside the UK must appoint a UK Responsible Person with responsibilities related to registration, documentation, conformity, and regulatory cooperation.

Digital products seeking NHS use may also be assessed through the Digital Technology Assessment Criteria. DTAC covers clinical safety, data protection, technical security, interoperability, usability, and accessibility.

Legal marketability and healthcare-system readiness are therefore separate conditions. A product may secure the appropriate regulatory route and still lack the local evidence, assurance package, or service proposition needed by its intended NHS customer.

England’s 10 Year Health Plan also changes what a relevant value proposition looks like. Its three shifts center on community-based care, digital delivery, and prevention.

Domestically, a Korean remote-monitoring platform may be positioned around technical accuracy. But in an English-language proposition, the same product may need to show how it supports care closer to home, enables earlier intervention, strengthens patient self-management, and improves continuity across neighborhood services.

Local Credibility Should Come Before Sales

Jewell said successful engagement depends on a company’s willingness to adapt with local stakeholders.

“Successful engagement tends to come from a willingness to adapt: shaping the solution with local stakeholders, responding to feedback from early interactions, and demonstrating that the product can flex to fit the realities of the system rather than expecting the system to adapt around it.”

That process also depends on choosing an entry point that can help the company understand the healthcare system before it begins pursuing commercial opportunities.

“There’s also value in identifying the right entry points, whether through research collaborations, innovation programmes, or clinical champions, rather than approaching organizations cold,”

Jewell said.

A research institution, clinical partner, or innovation program should not be viewed only as a source of introductions. The right partner can help a company challenge its intended use, map the local pathway, prepare an evidence plan, and identify the decision-makers who matter.

Hence, the first overseas relationship should help answer a difficult question: which part of the domestic adoption case still does not make sense in this market?

Korea Is Beginning to Support Overseas Adaptation

The Korea Health Industry Development Institute reorganized its 2026 ICT-Based Medical System Overseas Expansion Support Program around strategy development, overseas demonstration, and network building.

The KRW 5.546 billion program includes local business-model development and pilot operation intended to generate export, revenue, and market-entry outcomes. Its structure recognizes that cross-border healthtech commercialization requires market understanding, local testing, and institutional relationships rather than export promotion alone.

The National Institute for Health and Care Research and KHIDI have also established a GBP 2.8 million smart clinical trials partnership supporting joint research, feasibility work, pilot studies, capacity building, and knowledge exchange.

Beyond what seems to be a simple NHS sales channel, the value of this partnership lies in helping Korean and UK researchers create shared evidence and relationships that can strengthen local credibility.

England is also trying to reduce repeated evaluation through the National HealthTech Access Programme and the planned NHS Innovator Passport. Even so, NHS England has stated that purchasing organizations will still assess suitability for local deployment, including operational risk.

The policy direction is instructive for Korean founders. Standardized evidence may become more portable, while local pathway fit, population relevance, service economics, and deployment suitability still require judgment inside the destination system.

Korean Founders Must Rebuild the Case Before They Sell

A Korean healthtech company preparing for global entry should identify the exact jurisdiction, care pathway, patient population, and institutional buyer it intends to serve. “Entering the UK” is not specific enough to guide evidence, regulation, partnership, or commercial strategy.

Founders should separate the proof they already possess from the proof the destination market still requires. Domestic approval and hospital performance can establish credibility, while local validation may still be needed to address population differences, technical environments, and care practices.

The company also needs a local institution capable of interpreting the system. That partner may be a hospital, university, research network, innovation program, regulatory specialist, or market-access organization, depending on the unresolved question.

Jewell expects healthcare evaluation to become more coordinated and system-led during the coming years.

“The biggest shift will be a move towards much more structured, system-led approaches to evaluating and adopting innovation, rather than the relatively fragmented models we still see in places.”

This direction will favor companies that connect their products with local priorities, defined healthcare pathways, and credible routes into the market before pursuing sales.

The Product Travels First, but Credibility Arrives Later

International expansion can make a healthtech company appear global before its adoption model has become locally credible. Regulatory entry, distributor interest, and overseas pilots can create momentum, but none removes the need to understand the healthcare system receiving the product.

The strongest Korean healthtech exporters will carry more than just the technology abroad. They will question which domestic assumptions remain valid, which evidence needs rebuilding, and which local relationships can turn foreign interest into trusted use.

A product can cross a border through a shipment or software deployment. Credibility crosses only after the company proves that the technology truly belongs inside the new healthcare system.

Key Takeaway

• Korean medtech exports are growing: South Korea exported about USD 5.37B in 2025, but exports don’t equal sustained adoption.
• Domestic proof is a starting point: Korean approvals and clinical evidence matter, but most markets require local validation.
• Market entry is system fit: Regulation, reimbursement, digital assurance, and policy priorities reshape adoption.
• Medical AI needs local validation: A 2026 Nature Health review found performance can drop across different data, populations, coding, and practice settings.
• Credibility is locally earned: Startups gain trust by adapting with stakeholders, not expecting system change.
• Korea is enabling adaptation: KHIDI’s 2026 program and UK-Korea trials partnership support local testing and evidence building.
• Credibility lags the product: Technology can travel first, but adoption requires rebuilding system-specific fit.

---

– Stay Ahead in Korea’s Startup Scene –
Get real-time insights, funding updates, and policy shifts shaping Korea’s innovation ecosystem.
Follow KoreaTechDesk on LinkedIn, X (Twitter), Threads, Bluesky, Telegram, Facebook, and WhatsApp Channel.

---

Looking to connect with verified Korean companies building globally?
Explore curated company profiles and request direct introductions through beSUCCESS Connect.

The post Korean Healthtech Must Rebuild Its Adoption Case Before Entering Global Markets first appeared on KoreaTechDesk | Korean Startup and Technology News.